Research Article
Peripheral Blood WT1 Expression Predicts Relapse in AML Patients Undergoing Allogeneic Stem Cell Transplantation
Table 1
Characteristics and relapse incidence of AML patients grouped according to PB-WT1/ABL × 104 ≥ 5 or <5 before allo-SCT.
| | Variable | Total | PB-WT1/ABL × 104 ≥ 5 | PB-WT1/ABL × 104 < 5 | | | () | () | () |
| | Median age range | 51 (24–63) | 49 (42–63) | 51 (24–63) | NS | | Disease phase at allo-SCT | | | | | | First CR | 22 (92%) | 10 (91%) | 12 (92%) | NS | | Second | 2 (8%) | 1 (9%) | 1 (8%) | | or subsequent remission | | | | | Specific molecular marker | | | | | | Flt3-ITD | 4 (17%) | 0 | 4 (31%) | 0.04 | | NPM-1 mutation | 6 (25%) | 5 (45%) | 1 (8%) | 0.03 | | Donor source | | | | | | Sibling | 8 (33%) | 6 (55%) | 2 (15%) | 0.04 | | MUD | 16 (67%) | 5 (45%) | 11 (85%) | | Conditioning | | | | | | MAC | 11 (46%) | 5 (45%) | 6 (46%) | NS | | RIC | 13 (54%) | 6 (55%) | 7 (54%) | | Stem cells source | | | | | | BM | 3 (12%) | 0 | 3 (23%) | NS | | PB | 21 (88%) | 11 (100%) | 10 (77%) | | Posttransplant relapse | 12 (50%) | 8 (73%) | 4 (31%) | 0.04 | | Median time | 6 | 5 months | 6 months | NS | | (range) | (2–12) | (2–9) | (6–12) |
|
|
CR: complete remission; MUD: matched unrelated donor; UCB: umbilical cord blood; MAC: myeloablative conditioning; RIC: reduced-intensity conditioning; BM: bone marrow; PBSC: peripheral blood stem cells; NS: nonsignificant.
|
